Abnormal hepatic perfusion index predicts recurrence of colorectal carcinoma

Abstract

HPI predicts the risk of recurrent colorectal carcinoma, and this measurement should be included in the panel of prognostic markers in future clinical trials.

Diagnosis of hepatic inflammatory pseudotumor by fine-needle biopsy

“… 9 The hepatic perfusion index, which is defined as the ratio of the gradient of hepatic arterial to total hepatic blood flow, has been proven to be sensitive to differences in liver perfusion associated with established metastatic liver disease on imaging and can be used as a histopathological indicator of prognosis in some cases. 10 , 11 HPD can be divided into vessel abnormalities, hepatic focal lesions, hepatic perfusion disorders, and other causes. HPD also occurs in acute inflammatory diseases of surrounding organs, such as acute pancreatitis and cholecystitis.…”

Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy

“…Subsequently, HPI measurement methodology was adapted to dynamic CT, Doppler ultrasound, and finally to dynamic contrast-enhanced MR Imaging (DCE-MRI). HPI has been demonstrated to be a prognostic indicator of early liver recurrence, both in colorectal and in esophageal cancer patients [6][7][8] . In these studies, HPI was determined preoperatively in patients without metastases who underwent curative resection of the primary tumor, and patients with higher HPI presented shorter disease free and overall survival.…”